Heranba Industries Limited · NSE:HERANBA

Heranba Industries — Q3 FY2022 Earnings Presentation

27 slides from Heranba Industries's earnings presentation, January 2022

  1. Slide 1: Investor Presentation Q3FY22

    INVESTOR Presentation JANUARY 2022 || Q3FY22 heranba.co.in

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Heranba Industries Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any se

  3. Slide 3: Contents

    CONTENTS COMPANY OVERVIEW 01 SLIDE 04 MANAGEMENT TEAM 02 SLIDE 11 QUARTERLY PERFORMANCE 03 SLIDE 14 FINANCIAL PERFORMANCE 04 SLIDE 18 STRATEGY FOR GROWTH 05 SLIDE 23

  4. Slide 4: Company Overview

    HERANBA AT GLANCE SLIDE 05 OUR JOURNEY SLIDE 06 VALUE CHAIN SLIDE 07 INTERMEDIARIES SLIDE 08 TECHNICALS SLIDE 09 FORMULATIONS SLIDE 10 COMPANY Overview

  5. Slide 5: Heranba at a Glance

    HERANBA at a Glance 4 60+ 650+ Manufacturing Facilities Countries Presence Employees (as of FY21) 71% 9400+ 41% Revenue from Institutional customers** Dealers across India Revenue from Exports as % of sales (as of 9M FY22) (as of 9M FY22) Approx. 25% 32.38% Revenue from Top 10 ROE# customers (as of

  6. Slide 6: Our Journey

    Our Journey 2020 2021 2006 EXPORTS INITIAL PUBLIC OFFERING  Exported Technicals and  Listed on BSE & NSE BRANDED FORMULATIONS Formulations to more than 60  Commissioned Unit No. 4 in Vapi 1996  Forward Integrated into Branded Formulations through its own countries in the international markets di

  7. Slide 7: Value Chain

    Value Chain Value Chain Manufacturing Process  HIL manufactures a wide range of products, and each product has its own unique manufacturing process  The Company specializes in the manufacturing processes that mainly include chemical reactions of: Ammonolysis Hydrolysis Favorski Reaction Cyanation

  8. Slide 8: Intermediaries

    Intermediaries Intermediates Cypermethric Acid High CIS CMA Chloride (CMAC) High CIS CMAC High Trans CMA High Trans CMAC Bromobenzenes End-use Metaphenoxy Intermediates manufactured are for Company’s own captive Benzaldehyde (MPBD) consumption for manufacturing various Technicals and Formulations he

  9. Slide 9: Technicals

    Technicals Herbicides  Glyphosate  Metribuzin  Clodinofop Insecticides  Cypermethrin  Deltamethrin  Alpha Cypermethrin  Acephate  Lambda Cyhalothrin  Permethrin Technicals  Profenophos  Temephos  Theta Cypermethrin  Thiamethoxam  Imidacloprid Fungicides  Tricyclazole  Hexaconazole he

  10. Slide 10: Formulations

    Formulations Herbicides Revenue from Technical and Formulations  Glory  Glory 71 (₹ IN MILLION)  Chakde  Shera  Heraquat  Pendant  Zinta  Atria Insecticides  Jayam  Progress Plus  Param  Cypraplus  Dyken Formulations 8,570  Mantra  Astron 7,401 7,280 6,481  Signor  Prompt 4,971  Cy

  11. Slide 11: Management Team

    ABOUT PROMOTERS SLIDE 12 LEADERSHIP TEAM SLIDE 13 MANAGEMENT Team

  12. Slide 12: Experienced Promoters with Domain Knowledge

    Experienced Promoters with Domain Knowledge Promoters having a cumulative experience of more than six decades Mr. Sadashiv K. Shetty Mr. Raghuram K. Shetty CHAIRMAN AND EXECUTIVE DIRECTOR MANAGING DIRECTOR  Holds a bachelor’s (physics and chemistry) and master’s (chemistry) degree  Holds a bachelo

  13. Slide 13: Quarterly Performance

    FINANCIAL HIGHLIGHTS SLIDE 15 KEY RATIOS SLIDE 16 FINANCIAL SUMMARY SLIDE 17 QUARTERLY Performance

  14. Slide 14: Q3FY22 Financial Highlights

    Q1FY22 Financial Highlights Revenue from Operations at EBITDA (incl. other income) at ₹3,953.94 million in Q3FY22 as ₹763.49 million in Q3FY22 as compared to ₹3324.73 million in compared to ₹651.79 million in Q3FY21 – growth of 18.93% Y-o- Q3FY21 – growth of 17.14% Y-o- Y and growth of 11.87% Q-o-Q.

  15. Slide 15: Quarterly Performance

    Quarterly Performance Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Business Mix Operations and EBITDA Margin (₹ IN MILLION) (IN ₹ MILLION & %) (₹ IN MILLION & %) (IN %) 11% 13.52% 19% 13.45% 19.60% 19.31% 18.77% 3,953.94 3,534.35 3,324.73 43% 456.15 12.91% 27% 763.49 534.67 651.79 663

  16. Slide 16: Profit & Loss Summary (Quarterly)

    Profit & Loss Summary (Quarterly) (₹ IN MILLION) PARTICULARS Q3FY21 Q2FY22 Q3FY22 Revenue from Operations 3,324.73 3,534.35 3,953.94 Other Income 8.18 51.70 51.28 Total Revenue 3,332.91 3,586.05 4,005.22 Total Expenses 2,728.42 2,971.97 3,292.54 Profit Before Tax 604.49 614.08 712.68 Total Tax Expen

  17. Slide 17: Financial Performance

    KEY RATIOS SLIDE 19 FINANCIAL SUMMARY SLIDE 21 FINANCIAL Performance

  18. Slide 18: Key Ratios

    KEY Ratios Net Revenue from EBITDA(incl. Other Rev) PAT and PAT Margin Net Debt/(Cash) and Operations and EBITDA Margin Equity (₹ IN MILLION) (IN ₹ MILLION & %) (₹ IN MILLION & %) (₹ IN MILLION) (129.19) 13.31% 12.66% 12,186.47 (345.01) 11,002.35 19.25% 18.74% 10.26% 10,044.44 9,513.74 15.33% 13.82%

  19. Slide 19: Business Mix

    Business Mix Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market Revenue from Operations Revenue from Exports (IN %) (% OF SALES) Export Revenue Split: Technical and Formulations Export 32% 36% 39% 41% 39% 48% 49% 49% 9% 9% 13

  20. Slide 20: Profit & Loss Summary

    Profit & Loss Summary (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 9M FY22 Revenue from Operations 10,044.44 9,513.74 12,186.47 11,002.35 Other Income 73.94 165.32 70.30 145.71 Total Revenue 10,118.38 9,679.06 12,256.77 11,148.06 Total Expenses 8,897.18 8,390.64 10,173.92 9,178.20 Profit Before Tax 1,2

  21. Slide 21: Balance Sheet (1/2)

    Balance Sheet (1/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 H1 FY22 Non-Current Assets Property, plant and equipment 511.39 954.41 1,334.35 1,388.88 Capital work-in-progress 159.70 377.72 96.95 209.76 Financial Assets: (i) Investments 0.24 37.31 100.98 20.86 (ii) Other Financial Assets 71 84.27 24

  22. Slide 22: Balance Sheet (2/2)

    Balance Sheet (2/2) (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 H1 FY22 Equity and liabilities Equity Equity share capital 390.56 390.56 400.13 400.13 Other equity 1891.2 2817.93 4881.21 5808.32 Total Equity 2281.76 3208.49 5281.34 6208.45 Liabilities Non-Current Liabilities Financial Liabilities (i)

  23. Slide 23: Cashflow Statement

    Cashflow Statement (₹ IN MILLION) PARTICULARS FY19 FY20 FY21 H1 FY22 Cash Flow from Operations 877.02 542.11 603.98 -81.77 Cash Flow from Investing Activities -373.79 -520.39 -407.13 -305.24 Cash Flow from financing Activities -411.35 -199.43 619.01 -72.08 Net increase/ (decrease) in cash and cash e

  24. Slide 24: Strategy for Growth

    COMPETITIVE STRENGTHS SLIDE 26 BUSINESS STRATEGY SLIDE 27 Strategy for Growth

  25. Slide 25: Competitive Strengths

    Competitive Strengths Experienced Wide range of Diversified Product Promoters and products across Customer Base Registration Management Team value chain enabling global outreach Exports to more Integrated Wide Distribution than 60 countries Manufacturing Network Units heranba.co.in 25

  26. Slide 26: Business Strategy

    Business Strategy Well positioned to exploit opportunities offered by growth in Agrochemicals. Entering Highly Strengthening of Enhancing Enhancing Branded Regulated USA R&D Facility Production Formulation Formulations and and Europe Capabilities & Technicals in Public Health markets International M

  27. Slide 27: Thank You

    THANK YOU CONTACT US: Investor Relations Kanav Khanna kkhanna@christensenir.com Diwakar Pingle dpingle@christensenir.com CORPORATE OFFICE Heranba Industries Ltd. 101/102, Kanchanganga, Factor y Lane, Borivali (W), Mumbai – 400 092, India Tel : 91-22-2898 7912/14, 91-22-2898 2133/44, 91-22-2898 4439,

Heranba Industries — Q3 FY2022 Earnings Presentation on 6ix